Differential Anti-Proliferative and Anti-Migratory Activities of Ursolic Acid, 3--Acetylursolic Acid and Their Combination Treatments with Quercetin on Melanoma Cells
Overview
Molecular Biology
Affiliations
We evaluate how 3-acetylation modulates the in vitro activity of ursolic acid in melanoma cells alone or in combination treatments with quercetin. Anti-proliferative studies on A375 cells and adult human dermal fibroblasts included analyses on cell cycle distribution, caspase activity, phosphatidylserine translocation, cell morphology and Bax/Bcl-2 protein expression. Then, 2D and 3D migration of B16F10 cells were studied using scratch and Transwell assays, respectively. Ursolic acid and 3--acetylursolic acid have shown similar GI on A375 cells (26 µM vs. 32 µM, respectively) significantly increased both early and late apoptotic populations, activated caspases 3/7 (48-72 h), and enhanced Bax whilst attenuating Bcl-2 expression. Ursolic acid caused elevation of the sub-G1 population whilst its 3-acetyl derivative arrested cell cycle at S phase and induced strong morphological changes. Combination treatments showed that ursolic acid and quercetin act synergistically in migration assays but not against cell proliferation. In summary, 3--acetylursolic acid maintains the potency and overall apoptotic mechanism of the parent molecule with a more aggressive influence on the morphology of A375 melanoma cells but the 3-acetylation suppresses its anti-migratory properties. We also found that ursolic acid can act in synergy with quercetin to reduce cell migration.
Moralev A, Zenkova M, Markov A ACS Pharmacol Transl Sci. 2024; 7(11):3358-3384.
PMID: 39539268 PMC: 11555519. DOI: 10.1021/acsptsci.4c00422.
Jain N, Tailang M, Chandrasekaran B, Khazaleh N, Thangavel N, Makeen H Front Pharmacol. 2024; 15:1290398.
PMID: 38505421 PMC: 10949534. DOI: 10.3389/fphar.2024.1290398.
Grudzinska M, Stachnik B, Galanty A, Soltys A, Podolak I Molecules. 2023; 28(23).
PMID: 38067491 PMC: 10707933. DOI: 10.3390/molecules28237763.
Senobar Tahaei S, Kulmany A, Minorics R, Kiss A, Szabo Z, German P Int J Mol Sci. 2023; 24(18).
PMID: 37762056 PMC: 10531082. DOI: 10.3390/ijms241813749.
Soltys A, Galanty A, Grabowska K, Pasko P, Zagrodzki P, Podolak I Pharmaceuticals (Basel). 2023; 16(7).
PMID: 37513877 PMC: 10383022. DOI: 10.3390/ph16070965.